Guardion Health Sciences Inc Revenue Growth Rates (GHSI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Guardion Health Sciences Inc   (NASDAQ: GHSI)
 

GHSI's Revenue Growth by Quarter and Year

Guardion Health Sciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GHSI Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.07
1st Quarter March 2.18
FY 2.25

GHSIs Annual Revenue
Guardion Health Sciences Inc 's Revenue in the fiscal year 2023 $ 11.39 millions
Guardion Health Sciences Inc 's Revenue in the fiscal year 2022 $ 10.52 millions
Guardion Health Sciences Inc 's Revenue in the fiscal year 2021 $ 7.23 millions
Guardion Health Sciences Inc 's Revenue in the fiscal year 2020 $ 1.89 millions
Guardion Health Sciences Inc 's Revenue in the fiscal year 2019 $ 0.90 millions




GHSI Revenue second quarter 2024 Y/Y Growth Comment
Guardion Health Sciences Inc reported drop in Revenue in the second quarter 2024 by -96.76% to $ 0.07 millions, from the same quarter in 2023.
This represents worst decline in recent Company history.

Looking into second quarter 2024 results within Major Pharmaceutical Preparations industry 229 other companies have achieved higher Revenue growth. While Guardion Health Sciences Inc ' s Revenue meltdown of -96.76% ranks overall at the positon no. 3836 in the second quarter 2024.


GHSI Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 7.69 % 3.8 % 1215 %
3rd Quarter September - 17.7 % -33.65 % 1160 %
2nd Quarter June -96.76 % -6.25 % 96.72 % 2.52 %
1st Quarter March -6.84 % 11.43 % 813.04 % -8 %
FY   - 7.19 % 28.91 % -

Financial Statements
Guardion Health Sciences Inc 's second quarter 2024 Revenue $ 0.07 millions GHSI's Income Statement
Guardion Health Sciences Inc 's second quarter 2023 Revenue $ 2.25 millions Quarterly GHSI's Income Statement


GHSI Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 19.51 % 30.62 % -16.51 %
3rd Quarter September - 9.33 % -12.92 % 158.2 %
2nd Quarter June -96.66 % -3.85 % 14.29 % 430.43 %
1st Quarter March -25.85 % -14.29 % -20.15 % 15 %
FY (Year on Year)   - 7.19 % 28.91 % -


Back to GHSI Growth rate Comparisons >> Back to GHSI Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #230
Healthcare Sector #605
Overall #3836

Revenue Y/Y Growth Statistics
High Average Low
1213.59 % 171.84 % -96.76 %
(Jun 30 2022)   (Jun 30 2024)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #230
Healthcare Sector #605
Overall #3836
Revenue Y/Y Growth Statistics
High Average Low
1213.59 % 171.84 % -96.76 %
(Jun 30 2022)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Guardion Health Sciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
424.53 % 40.76 % -96.65 %
(Jun 30 2021)  


GHSI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Guardion Health Sciences Inc disclosed fall in Revenue from the first quarter by -96.66% to $ 0.07 millions, from $ 2.18 millions achived in the previous reporting period.

But that's not important problem, as Guardion Health Sciences Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 241 other companies have achieved higher Revenue quarter on quarter growth. While Guardion Health Sciences Inc 's Revenue growth quarter on quarter, overall rank is 3983.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #242
Healthcare Sector #636
Overall #3983
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #242
Healthcare Sector #636
Overall #3983
Revenue Q/Q Growth Statistics
High Average Low
424.53 % 40.76 % -96.65 %
(Jun 30 2021)  


GHSI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Guardion Health Sciences Inc disclosed fall in Revenue from the first quarter by -96.66% to $ 0.07 millions, from $ 2.18 millions achived in the previous reporting period.

But that's not important problem, as Guardion Health Sciences Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 241 other companies have achieved higher Revenue quarter on quarter growth. While Guardion Health Sciences Inc 's Revenue growth quarter on quarter, overall rank is 3983.


Guardion Health Sciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 7.65 $ 9.82 $ 9.98 $ 9.77 $ 9.40
Y / Y Revenue Growth (TTM) -18.63 % 2.88 % 7.2 % 6.07 % -8.5 %
Year on Year Revenue Growth Overall Ranking # 1614 # 554 # 227 # 230 # 107
Seqeuential Revenue Change (TTM) -22.15 % -1.57 % 2.14 % 3.96 % -1.57 %
Seq. Revenue Growth (TTM) Overall Ranking # 2151 # 1418 # 771 # 2584 # 1371


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2024 Guardion Health Sciences Inc reported a fall in Revenue by -18.63% year on year, to $8 millions, compare to the 2.88% growth at Mar 31 2024.

In the Healthcare sector 289 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 554 to 1614.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 129
Healthcare Sector # 290
Overall # 1614

Revenue TTM Y/Y Growth Statistics
High Average Low
437.74 %
 89.21 %
-14.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 129
Sector # 355
S&P 500 # 2151
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2024 Guardion Health Sciences Inc reported a fall in Revenue by -18.63% year on year, to $8 millions, compare to the 2.88% growth at Mar 31 2024.

In the Healthcare sector 289 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 554 to 1614.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 129
Healthcare Sector # 290
Overall # 1614

Revenue TTM Y/Y Growth Statistics
High Average Low
437.74 %
89.21 %
-14.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 129
Sector # 355
S&P 500 # 2151




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GHSI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Organon and Co -0.06%$ -0.062 millions
Royalty Pharma Plc-0.17%$ -0.174 millions
Repligen Corp-0.21%$ -0.207 millions
Whitehawk Therapeutics Inc -0.37%$ -0.371 millions
3m Company-0.45%$ -0.446 millions
T2 Biosystems Inc -0.61%$ -0.611 millions
Hcw Biologics Inc -0.63%$ -0.635 millions
Enhabit Inc -0.65%$ -0.648 millions
Sonoma Pharmaceuticals Inc -1.05%$ -1.050 millions
Encision Inc -1.36%$ -1.358 millions
Vaso Corporation-1.40%$ -1.399 millions
Teladoc Health Inc -1.53%$ -1.527 millions
Zimvie Inc -1.55%$ -1.549 millions
Alpha Pro Tech Ltd -1.65%$ -1.645 millions
Novavax inc -2.11%$ -2.107 millions
Agile Therapeutics Inc-2.23%$ -2.232 millions
Fresenius Medical Care Ag-2.33%$ -2.330 millions
Avantor Inc -2.36%$ -2.357 millions
Aspira Women s Health inc -2.81%$ -2.810 millions
Viatris Inc -3.11%$ -3.113 millions
Catheter Precision Inc -3.13%$ -3.125 millions
Nrc Health-3.15%$ -3.153 millions
Akoya Biosciences Inc -3.16%$ -3.158 millions
Neuronetics Inc -3.55%$ -3.547 millions
Mettler toledo International Inc -3.60%$ -3.601 millions
Prestige Consumer Healthcare Inc -4.18%$ -4.181 millions
Dentsply Sirona Inc -4.28%$ -4.280 millions
Waters Corporation-4.33%$ -4.327 millions
Accelerate Diagnostics Inc -4.39%$ -4.394 millions
Envista Holdings Corporation-4.50%$ -4.499 millions


About Guardion Health Sciences Inc Revenue Growth Rates (GHSI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Guardion Health Sciences Inc (CIK 1642375).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-24-031604
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Guardion Health Sciences Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.